First AD

Second AD

Data from the following clinical trials are discussed:

+ breast cancer identifies recurrent pathway alterations associated with anti-HER2 resistance and new therapeutic vulnerabilities

GS1-05: Datopotamab deruxtecan (Dato-DXd) in advanced/metastatic HER2- breast cancer: results from the phase 1 TROPION-PanTumor01 study

GS04-09: Quality-of-life results from OlympiA: a phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after neoadjuvant chemotherapy in patients with germline 

Breast Cancer

ELI-22-OSD1261 - /clinical/colorectal-cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

HER2-Positive Breast Cancer: A Review of Data from the SABCS 2021 Virtual Meeting

The Talk

After discussing a few more key datasets from the SABCS 2021 Virtual Meeting, expert panelists discuss how they would approach treatment in several subsets of breast cancer. 

SABCS 2021: Novel Approaches to Breast Cancer Management